Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus

被引:9
作者
Radzicka-mularczyk, Sandra [1 ]
Zaborowski, Mikolaj P. [2 ]
Brazert, Jacek [1 ]
Pietryga, Marek [1 ]
机构
[1] Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Obstet & Womens Dis, Polna St 33, PL-60535 Poznan, Poland
[2] Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Gynecol Oncol, Poznan, Poland
来源
MINERVA ENDOCRINOLOGY | 2021年 / 46卷 / 04期
关键词
Nicotinamide phosphoribosyltransferase; Obesity; Body Mass Index; Diabetes; Gestational; Adipocyto-kines; Pregnancy; Glucose intolerance; MESSENGER-RNA EXPRESSION; PREGNANT-WOMEN; GLUCOSE; FAT; HYPERGLYCEMIA; TISSUE; LEVEL;
D O I
10.23736/S2724-6507.20.03280-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Visfatin is an adipokine produced and secreted by the adipose tissue. It exerts an insulin-like effect by the insulin receptor-1 and has a hypoglycemic effect. We aimed to investigate how serum visfatin changes in women with gestational diabetes mellitus (GDM), and whether it is predictive of neonatal outcomes. METHODS: Visfatin levels were prospectively measured in peripheral blood serum by enzyme immunoassay in 210 pregnant women, 156 of which were diagnosed with GDM, 18 of which suffered from pregnancy-induced hypertension (PIH) and 36 healthy controls. RESULTS: Patients with obesity class II (median=2.562 ng/mL) and class III (median=6.2940 ng/mL) had higher serum visfatin than overweight patients (median=0.735 ng/mL); (Mann-Whitney U test, P=0.037 and P=0.023, respectively). In GDM patients with BMI above 30, serum visfatin was associated to glycosylated hemoglobin (Spearman correlation test, R=0.26, P=0.045). Women with BMI above 25 treated with insulin had lower serum visfatin levels than those treated with diet only (Mann-Whitney U test, P=0.045). No correlation was found between visfatin and parameters of lipid profile such as HDL, LDL, or triglycerides (Spearman correlation tests, R=-0.051,-0.1, 0.0019; P=0.54, 0.29, 0.98, respectively). We observed that visfatin was not associated with birth weight (Spearman correlation test, R=-0.014, P=0.86) or adverse neonatal outcome as measured by umbilical artery pH below 7.25 (Mann-Whitney U test, P=0.55) or Apgar score below 10 (Mann-Whitney U test, P=0.21). CONCLUSIONS: In GDM patients with higher BMI, serum visfatin was elevated, correlated positively with glycosylated hemoglobin, and decreased upon treatment with insulin therapy. (Cite this article as: Radzicka-Mularczyk S, Zaborowski MP, Brazert J, Pietryga M. Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus. Minerva Endocrinol 2021;46:396-405. DOI:10.23736/S27246507.20.03280-0)
引用
收藏
页码:396 / 405
页数:10
相关论文
共 40 条
[1]   Visfatin: Structure, function and relation to diabetes mellitus and other dysfunctions [J].
Adeghate, Ernest .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (18) :1851-1862
[2]   Plasma visfatin concentrations and fat depot-specific mRNA expression in humans [J].
Berndt, J ;
Klöting, N ;
Kralisch, S ;
Kovacs, P ;
Fasshauer, M ;
Schön, MR ;
Stumvoll, M ;
Blüher, M .
DIABETES, 2005, 54 (10) :2911-2916
[3]   The Relative Contribution of Prepregnancy Overweight and Obesity, Gestational Weight Gain, and IADPSG-Defined Gestational Diabetes Mellitus to Fetal Overgrowth [J].
Black, Mary Helen ;
Sacks, David A. ;
Xiang, Anny H. ;
Lawrence, Jean M. .
DIABETES CARE, 2013, 36 (01) :56-62
[4]   Gestational diabetes mellitus: risks and management during and after pregnancy [J].
Buchanan, Thomas A. ;
Xiang, Anny H. ;
Page, Kathleen A. .
NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (11) :639-649
[5]   Increased plasma visfatin concentrations in women with polycystic ovary syndrome [J].
Chan, Te-Fu ;
Chen, Yi-Ling ;
Chen, Hung-Hseng ;
Lee, Chien-Hung ;
Jong, Shiang-Bin ;
Tsai, Eing-Mei .
FERTILITY AND STERILITY, 2007, 88 (02) :401-405
[6]   Decreased plasma visfatin concentrations in women with gestational diabetes mellitus [J].
Chan, Te-Fu ;
Chen, Yi-Ling ;
Lee, Chien-Hung ;
Chou, Fan-Hao ;
Wu, Lee-Chen ;
Jong, Shiang-Bin ;
Tsai, Eing-Mei .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2006, 13 (05) :364-367
[7]   Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus [J].
Chen, MP ;
Chung, FM ;
Chang, DM ;
Tsai, JCR ;
Huang, HF ;
Shin, SJ ;
Lee, YJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :295-299
[8]   First-Trimester Maternal Abdominal Adiposity Predicts Dysglycemia and Gestational Diabetes Mellitus in Midpregnancy [J].
De Souza, Leanne R. ;
Berger, Howard ;
Retnakaran, Ravi ;
Maguire, Jonathon L. ;
Nathens, Avery B. ;
Connelly, Philip W. ;
Ray, Joel G. .
DIABETES CARE, 2016, 39 (01) :61-64
[9]   Effects of Pre-Pregnancy Body Mass Index and Gestational Weight Gain on Infant Anthropometric Outcomes [J].
Deierlein, Andrea L. ;
Siega-Riz, Anna Maria ;
Adair, Linda S. ;
Herring, Amy H. .
JOURNAL OF PEDIATRICS, 2011, 158 (02) :221-226
[10]   Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance [J].
Dogru, Teoman ;
Sonmez, Alper ;
Tasci, Ilker ;
Bozoglu, Ergun ;
Yilmaz, Mahmut Ilker ;
Genc, Halil ;
Erdem, Gokhan ;
Gok, Mahmut ;
Bingol, Necati ;
Kilic, Selim ;
Ozgurtas, Taner ;
Bingol, Sezin .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) :24-29